Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Carvana Co (CVNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Carvana Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Carvana Co trades at $65.66 (market cap $48.34B). The key difference: Carvana Co is far larger — about 10.8× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| ACAD | CVNA | |
|---|---|---|
Market Cap | $4.49B | $48.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $95.69 |
52-Week Low | $20.06 | $56.27 |
Enterprise Value | $3.69B | $50.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Carvana (CVNA) trades at $67.47, down 1.63% on the day, with a bullish technical signal and strong fundamental growth. Revenue surged to $20.32B in 2025, with net income reaching $1.41B, though Q2 2026 earnings are pending. Recent corporate actions include stock splits, and expansion news includes same-day delivery in Milwaukee.
The outlook is positive with analyst consensus at Buy and a $93.92 price target, but risks include high debt levels and competitive pressures. Upside potential exists from operational efficiency and market expansion, yet volatility from used-car market softness remains a concern for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
